Metabolic dysfunction-associated steatohepatitis affects approximately 115 million individuals globally, yet treatment options remain severely limited. This staggering patient population now faces renewed hope following UC San Diego’s clinical validation of ION224, a drug specifically designed to address the root causes of severe fatty liver disease.
Unlike traditional interventions focused primarily on weight management, ION224 directly inhibits acetyl-CoA carboxylase, an enzyme responsible for hepatic fat accumulation and inflammation. Clinical trial data demonstrates that 78 percent of treated patients achieved reduced liver fat content, while 65 percent showed decreased inflammation markers within 12 weeks. By contrast, only 12 percent of placebo recipients experienced comparable improvements. These findings underscore the critical need for mechanism-based therapies targeting the pathophysiology of MASH rather than relying solely on behavioral interventions.
Read the full article on GMJ Newsroom.
Was this article helpful?
